Abstract
Nicotine dependence remains a major global public health challenge, driven by the addictive potential of nicotine delivered through combustible and smokeless tobacco products. Nicotine exerts its effects primarily through activation of nicotinic acetylcholine receptors in the central nervous system, leading to dopamine release in reward pathways and reinforcing tobacco use. Despite widespread awareness of tobacco-related health risks, cessation is difficult due to withdrawal symptoms, craving, and neuroadaptations associated with chronic nicotine exposure. Nicotine Replacement Therapy (NRT) has emerged as a cornerstone pharmacological strategy for smoking cessation, providing controlled doses of nicotine without exposure to the toxic constituents of tobacco smoke.This review provides comprehensive pharmacological insights into the rational use of nicotine and NRT, focusing on their pharmacokinetic and pharmacodynamic properties. Key aspects such as absorption, distribution, metabolism, and elimination of nicotine are discussed, highlighting differences between smoking and therapeutic nicotine delivery systems. The neuropharmacological mechanisms underlying nicotine dependence, tolerance, and withdrawal are examined to explain the clinical effectiveness of NRT. Various NRT formulations, including transdermal patches, gums, lozenges, inhalers, and nasal sprays, are evaluated with respect to their onset of action, efficacy, and safety profiles. Clinical relevance is emphasized through discussion of NRT use in special populations, including individuals with cardiovascular disease, diabetes, mental health disorders, adolescents, and breastfeeding women. Evidence consistently indicates that NRT is significantly safer than continued tobacco use, with generally mild and localized adverse effects. Finally, future directions in nicotine harm reduction are explored, including combination therapies, personalized treatment approaches, and emerging non-combustible nicotine delivery systems. Overall, rational and evidence-based use of NRT represents an effective and safe approach to reducing nicotine dependence and tobacco-related morbidity and mortality.
Keywords
Nicotine, Nicotine Replacement Therapy, Pharmacokinetics, Neuropharmacology, Smoking Cessation
Introduction
Tobacco use remains one of the leading preventable causes of morbidity and mortality worldwide, contributing significantly to cardiovascular diseases, respiratory disorders, malignancies, and metabolic complications. According to global estimates, tobacco consumption accounts for more than eight million deaths annually, with a substantial proportion occurring in low- and middle-income countries. India represents one of the largest consumers of tobacco, with both smoked and smokeless forms widely prevalent. The high burden of tobacco use in India poses serious public health challenges due to early initiation, widespread cultural acceptance, and limited access to cessation services in certain regions [1,2]. Nicotine is the principal psychoactive component responsible for tobacco dependence. It produces addiction by rapidly activating nicotinic acetylcholine receptors in the central nervous system, leading to dopamine release in the mesolimbic reward pathway. Chronic exposure to nicotine results in neuroadaptations that reinforce compulsive tobacco use and precipitate withdrawal symptoms upon cessation. These withdrawal manifestations, including irritability, anxiety, impaired concentration, and intense craving, represent major barriers to successful quitting [3,4]. Behavioral interventions alone often prove insufficient for sustained abstinence, particularly in individuals with moderate to severe nicotine dependence. This has created a strong need for pharmacological approaches that target the neurobiological mechanisms of addiction. Nicotine Replacement Therapy provides a controlled and safer source of nicotine without exposure to toxic combustion products, thereby reducing withdrawal symptoms and cravings while allowing gradual dissociation from smoking behavior [5,6]. The present review aims to provide a comprehensive pharmacological overview of nicotine and Nicotine Replacement Therapy. It focuses on the pharmacokinetics of nicotine, its absorption, distribution, metabolism, and elimination, and highlights how these properties inform the rational clinical use of NRT in smoking cessation and tobacco harm reduction.
Reference
- World Health Organization. WHO global report on trends in prevalence of tobacco use 2000 to 2025. 4th ed. Geneva WHO; 2021.
- Ministry of Health and Family Welfare Government of India. Global Adult Tobacco Survey India 2016 to 2017. New Delhi MoHFW; 2018.
- Prochaska JJ, Benowitz NL. Current advances in research in treatment and recovery: Nicotine addiction. Science advances. 2019 Oct 16;5(10): eaay9763.
- Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacology Biochemistry and Behavior. 2001 Dec 1;70(4):439-46.
- Henningfield JE Fant RV Buchhalter AR Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005; 55:281 299.
- Stead LF Perera R Bullen C et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
- Benowitz NL Porchet H Jacob P. Nicotine dependence and tolerance in man pharmacokinetic and pharmacodynamic investigations. Prog Brain Res. 1989; 79:279 287.
- Le Houezec J Benowitz NL. Basic and clinical psychopharmacology of nicotine. Clin Chest Med. 1991; 12:681 699.
- Benowitz NL Jacob P. Determinants of nicotine intake while chewing nicotine gum. Clin Pharmacol Ther. 1987; 41:467 473.
- Henningfield JE London ED Benowitz NL. Arterial venous differences in plasma nicotine concentrations after cigarette smoking. JAMA. 1990; 263:2049 2050.
- Porchet HC Benowitz NL Sheiner LB. Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics. J Clin Invest. 1987; 80:1466 1471.
- Benowitz NL. Clinical pharmacology of nicotine. Annu Rev Med. 1986; 37:21 32.
- Hukkanen J Jacob P Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005; 57:79 115.
- Malaiyandi V Sellers EM Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005; 77:145 158.
- Benowitz NL Jacob P Jones RT Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine. J Pharmacol Exp Ther. 1982; 221:368 372.
- Dempsey D Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf. 2001; 24:277 322. • Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors native subtypes and their relevance. Trends Pharmacol Sci. 2006; 27:482–491.
- Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio M, et al. Acetylcholine receptors containing the beta two subunit are involved in the reinforcing properties of nicotine. Nature. 1998; 391:173–177.
- Maskos U, Molles BE, Pons S, Besson M, Guiard BP, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005; 436:103–107.
- Levin ED, Bettegowda C, Blosser J, Gordon J. AR R17779 an alpha seven nicotinic agonist improves learning and memory in rats. Behav Pharmacol. 1999; 10:675–680.
- Hajós M, Hurst RS, Hoffmann WE, Krause M, Wall TM, et al. The selective alpha seven nicotinic acetylcholine receptor agonist PNU 282987 enhances GABAergic synaptic activity and restores auditory gating deficits. J Pharmacol Exp Ther. 2005; 312:1213–1222.
- Aberger K, Chitravanshi VC, Sapru HN. Cardiovascular responses to nicotine microinjection in the ventrolateral medulla. Brain Res. 2001; 892:138–146.
- Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001; 70:439–446.
- Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005; 8:1445–1449.
- Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol. 2002; 53:606–617.
- Wonnacott S. Presynaptic nicotinic acetylcholine receptors. Trends Neurosci. 1997; 20:92–98.
- Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Rev. 2005; 48:420–437.
- Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, et al. Cigarette smoking saturates brain alpha four beta two nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006; 63:907–915.
- George O, Ghozland S, Azar MR, Cottone P, Zorrilla EP, et al. CRF CRF one system activation mediates withdrawal induced increases in nicotine self-administration. Proc Natl Acad Sci USA. 2007; 104:17198–17203.
- Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005; 55:281–299.
- Russell MA. The future of nicotine replacement therapy. Br J Addict. 1991;86(5):653–658.
- Benowitz NL. Neurobiology of nicotine addiction implications for smoking cessation treatment. Am J Med. 2008;121(4 Suppl 1): S3–S10.
- Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
- Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335(24):1792–1798.
- Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55(5):281–299.
- Benowitz NL, Jacob P. Nicotine absorption and cardiovascular effects with smokeless tobacco use comparison with cigarettes and nicotine gum. Clin Pharmacol Ther. 1988;44(1):23–28.
- Sutherland G, Russell MAH, Stapleton J, Feyerabend C, Ferno O. Nasal nicotine spray a rapid nicotine delivery system. Psychopharmacology. 1992;108(4):512–518.
- Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation. BMJ. 1999;318(7179):285–289.
- Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation. Tob Control. 2009;18(1):34–42.
- Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy systematic review and meta-analysis. Tob Induc Dis. 2010;8(1):8.
- Knight West O, Bullen C. Electronic cigarettes for the management of nicotine addiction. Subst Abuse Rehabil. 2016; 7:111 118.
- Vansickel AR, Cobb CO, Weaver MF, Eissenberg T. A clinical laboratory model for evaluating the acute effects of electronic cigarettes. Cancer Epidemiol Biomarkers Prev. 2010; 19:1945 1953.
- Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation. Lancet. 2013; 382:1629 1637.
- Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use. Sci Rep. 2014; 4:4133.
- Talih S, Balhas Z, Eissenberg T, Salman R, Karaoghlanian N, El Hellani A, et al. Effects of device characteristics on nicotine yield. Nicotine Tob Res. 2015; 17:150 157.
- Lunell E, Fagerstrom K, Hughes J, Pendrill R. Pharmacokinetic comparison of a novel nicotine pouch. Nicotine Tob Res. 2020; 22:1757 1763.
- Liu J, Rensch J, McEwan M, Gale N. Nicotine pharmacokinetics of oral nicotine pouches. Psychopharmacology. 2022; 239:2863 2873.
- Chapman F, McDermott S, Rudd K, McEwan M. Pharmacokinetic and subjective effects of nicotine pouches. Psychopharmacology. 2022; 239:2931 2943.
- McEwan M, Gale N, Hardie G, Proctor C. Toxicological assessment of tobacco free nicotine products. Regul Toxicol Pharmacol. 2021; 123:104937.
- Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf. 2001; 24:277 322.
- Woolf A, Burkhart K, Caraccio T, Litovitz T. Childhood poisoning involving nicotine patches. Pediatrics. 1997;99: e4.
- Hale TW. Medications and mothers’ milk. 14th ed. Amarillo: Hale Publishing; 2010.
- Smith TA, House RF, Croghan IT, Gauvin TR, Offord KP, Hurt RD. Nicotine patch therapy in adolescent smokers. Pediatrics. 1996; 98:659 667.
- Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, et al. Safety and efficacy of nicotine patch and gum in adolescents. Pediatrics. 2005; 115:407 414.
- Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine. J Am Coll Cardiol. 1997; 29:1422 1431.
- Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. Safety of transdermal nicotine in cardiac patients. N Engl J Med. 1996; 335:1792 1798.
- Persson LG, Hjalmarson A. Smoking cessation in patients with diabetes mellitus. Scand J Prim Health Care. 2006; 24:75 80.
- Williams JM, Hughes JR. Pharmacotherapy for tobacco dependence in mental illness. Psychiatr Ann. 2003; 33:457 466.
- Fagerstrom KO, Aubin HJ. Management of smoking cessation in psychiatric disorders. Curr Med Res Opin. 2009; 25:511 518.
- Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy. Tob Induc Dis. 2010; 8:8.
- Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy for smoking cessation. Tob Induc Dis. 2010;8(1):8.
- Hughes JR. Dependence on and abuse of nicotine replacement medications. Nicotine Tob Res. 2011;13(6):465–470.
- Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29(7):1422–1431.
- Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335(24):1792–1798.
- Foulds J, Hughes JR, Hyland A, Le Houezec J, McNeill A, Melvin C, et al. Barriers to use of FDA approved smoking cessation medications. Nicotine Tob Res. 2009;11(2):161–168.
- McNeill A, Foulds J, Bates C. Regulation of nicotine replacement therapies. Addiction. 2001;96(12):1757–1768.
- Russell MAH. The future of nicotine replacement. Br J Addict. 1991;86(5):653–658.
- Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
- Benowitz NL, Jacob P III. Suppression of nicotine intake during ad libitum cigarette smoking by high dose transdermal nicotine. J Pharmacol Exp Ther. 1998;287(3):958–962.
- Balfour DJK. The neurobiology of tobacco dependence. Nicotine Tob Res. 2004;6(6):899–912.
- Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55(5):281–299.
- Stapleton JA. Progress on nicotine replacement therapy for smokers. BMJ. 1999;318(7188):289–290.
- Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2007;3:CD005231.
- World Health Organization. Tobacco harm reduction approaches. WHO Technical Report Series. Geneva; 2020.
- Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation. Tob Control. 2009;18(1):34–42.
- Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of nicotine patch therapy. Clin Pharmacol Ther. 2006;80(6):600–608.
- Benowitz NL. Pharmacogenetics of nicotine addiction and treatment. Annu Rev Pharmacol Toxicol. 2008; 48:57–81.
- Hatsukami DK, Benowitz NL, Rennard SI, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res. 2006;8(2):169–191.
Prathamesh Chandankhede
Corresponding author
Vidyaniketan College of pharmacy, Anjangaon surji Amravati, Maharashtra, India
Bhakti Chipada
Co-author
Vidyaniketan College of pharmacy, Anjangaon surji Amravati, Maharashtra, India
Dr. Anand Khode
Co-author
Vidyaniketan College of pharmacy, Anjangaon surji Amravati, Maharashtra, India
Prathamesh Chandankhede*, Bhakti Chipada, Dr. Anand Khode, Pharmacological Insights into the Rational Use of Nicotine and Nicotine Replacement Therapy, Int. J. Sci. R. Tech., 2025, 2 (12), 425-436. https://doi.org/10.5281/zenodo.18056447
10.5281/zenodo.18056447
